The therapeutic potential of iron chelators

Bibliography

• RICHARDSON DR, PONKA P: The development of iron chelators to treat iron overload disease and their use as experimental tools to study intracellular iron metabo-lism. Am. J. Hematol. (1998) 58:299–305.
   PubMed Web of Science ®Google Scholar
• OLIVIERI NF, BRITTENHAM G: Iron chelating therapy and the treatment of thalassemia. Blood (1997) 89:739–761.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, PONKA P: Pyridoxal isonicotinoyl hydrazone and its analogues: Potential orally effective iron-chelating agents for the treatment of iron overload disease. J. Lab. Clin. Merl. (1998) 131:306–315.
   PubMed Web of Science ®Google Scholar
• MÜLLNER EW, KIIHN LC: A stem-loop in the 3' untrans-lated region mediates iron-dependent regulation of transferrin receptor mRNA stability in the cytoplasm. Cell (1998) 53:815–825.
   Google Scholar
• MÜLLNER EW, NEUPERT B, KUHN LC: A specific mRNA-binding factor regulates the iron-dependent stability of the cytoplasmic transferrin receptor mRNA. Cell (1989) 58:373–382.
   PubMed Web of Science ®Google Scholar
• HENTZE MW, KUHN LC: Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci. USA (1996) 93:8175–8182.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, PONKA P: The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta (1997) 1320:45–57.
   PubMed Web of Science ®Google Scholar
• BAKER E: Biologic screens for iron chelators. Birth Defects (1988) 23:49–61.
   PubMedGoogle Scholar
• O'HALLORAN TV: Transition metals in the control of gene expression. Science (1993) 261:715–725.
   Google Scholar
• MORGAN EH: Transferrin: biochemistry, physiology and clinical significance. Mol. Aspects Med. (1981) 4:1–123.
   Web of Science ®Google Scholar
• KLAUSNER RD, ASHWELL G, VAN RENSWOUDE J, HARFORD JB, BRIDGES KR: Binding of apotransferrin to K562 cells: Explanation of the transferrin cycle. Proc. Natl. Acad. Sci. USA (1983) 80:2263–2266.
   PubMed Web of Science ®Google Scholar
• MORGAN EH: Membrane transport of non-transferrin-bound iron by reticulocytes. Biochim. Biophys. Acta (1988) 943:428–439.
   PubMed Web of Science ®Google Scholar
• GUNSHIN H, MACKENZIE B, BERGER UV et al.: Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature (1997) 388:482–488.
   PubMed Web of Science ®Google Scholar
• FLEMING MD, TRENOR CC, SU MA et al.: Microcytic anemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nature Genet. (1997) 16:383–386.
   PubMed Web of Science ®Google Scholar
• FLEMING MD, ROMANO MA, SU MA, GARRICK LM, GARRICK MD, ANDREWS NC: Nramp2 is mutated in the anemic Belgrade (b) rat: Evidence of a role for Nramp2 in endosomal iron transport. Proc. Natl. Acad. Sci. USA (1998) 95:1148–1153.
   PubMed Web of Science ®Google Scholar
• WARDROP SL, RICHARDSON DR: The effect of intracel-lular iron concentration and nitrogen monoxide on Nramp2 expression and non-transferrin-bound iron uptake. Eur. J. Biochem. (1999) 263:41–49.
   PubMedGoogle Scholar
• PAGE MA, BAKER E, MORGAN EH: Transferrin and iron uptake by rat hepatocytes in culture. Am. J. Physiol. (1984) 246:G26–G33.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, BAKER E: The uptake of iron and transferrin by the human melanoma cell. Biochim. Biophys. Acta (1990) 1053:1–12.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, BAKER E: Two mechanisms of iron uptake from transferrin by melanoma cells: The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem. (1992) 267:13972–13979.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, BAKER E: Two saturable mechanismsof iron uptake from transferrin in human melanoma cells: The effect of transferrin concentration, chelators and metabolic probes on transferrin and iron uptake. J. Cell Physic)]. (1994) 161:160–168.
   PubMed Web of Science ®Google Scholar
• TRINDER D, MORGAN EH, BAKER E: The mechanisms ofiron uptake by rat fetal hepatocytes. Hepatology (1986) 6:852–858.
   PubMed Web of Science ®Google Scholar
• TRINDER D, ZAK 0, AISEN P: Transferrin receptor-independent uptake of diferric transferrin by human hepatoma cells with antisense inhibition of receptor expression. Hepatology (1996) 23:1512–1520.
   PubMed Web of Science ®Google Scholar
• OSAKI S, JOHNSON DA: Mobilization of liver iron by ferroxidase (ceruloplasmin). J. Biol. Chem. (1969) 244:5757–5758.
   PubMed Web of Science ®Google Scholar
• ROESER HP, LEE GR, NACHT S, CARTWRIGHT GE: The role of ceruloplasmin in iron metabolism. J. Clin. Invest. (1970) 49:2408–2417.
   PubMed Web of Science ®Google Scholar
• OSAKI S, JOHNSON DA, FRIEDEN E: The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I. J. Biol. Chem. (1971) 246:3018–3023.
   PubMed Web of Science ®Google Scholar
• YOUNG SP, FAHMY M, GOLDING S: Ceruloplasmin, transferrin and apotransferrin facilitate iron release from human liver cells. FEBS Lett. (1997) 411:93–96.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR: The role of ceruloplasmin and ascorbate in cellular iron release. J. Lab. Clin. Med. (1999) 134:454–465.
   PubMedGoogle Scholar
• HARRISON PM, AROSIO P: The ferritins: molecular properties, iron storage function and cellular regula-tion. Biochim. Biophys. Acta (1996) 1275:161–203.
   PubMed Web of Science ®Google Scholar
• JACOBS A, WORWOOD M: Ferritin in serum. Clinical and biochemical implications. N Engl. J. Med. (1975) 292:951–956.
   PubMed Web of Science ®Google Scholar
• SAMANIEGO F, CHIN J, IWAI K, ROUAULT TA, KLAUSNERRD: Molecular characterization of a second iron-responsive element binding protein, iron-regulatory protein 2. Structure, function, and post-translational regulation. J. Biol. Chem. (1994) 269:30904–30910.
   Web of Science ®Google Scholar
• GUO B, PHILLIPS JD, YU Y, LEIBOLD EA: Iron regulatesthe intracellular degradation of iron regulatory protein 2 by the proteasome. J. Biol. Chem. (1995) 270:21645–21651.
   PubMed Web of Science ®Google Scholar
• LARRICK JW, CRESSWELL P: Modulation of cell surface iron transferrin receptors by cellular density and the state of activation. J. Supramol. Struct. (1979) 11:579–586.
   PubMedGoogle Scholar
• CHAN SM, HOFFER PB, MARIC N, DURAY P: Inhibition of gallium-67 uptake in melanoma by an anti-human transferrin receptor monoclonal antibody. J. Mid: Med. (1987) 28:1303–1307.
   Google Scholar
• CHITAMBAR CR, ZIVKOVIC Z. Uptake of gallium-67 by human leukemic cells: Demonstration of transferrin receptor-dependent and transferrin receptor-independent mechanisms. Cancer Res. (1987) 47:3929–3934.
   PubMed Web of Science ®Google Scholar
• TROWBRIDGE IS, LOPEZ F: Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA (1982) 79:1175–1179.
   PubMed Web of Science ®Google Scholar
• WEINBERG ED: Iron withholding a defense against infection and neoplasia. Physiol. Rev. (1984) 64:65–102.
   PubMed Web of Science ®Google Scholar
• MARCUS DM, ZINBERG M: Measurement of serum ferritin by radioimmunoassay: results in normal individuals and patients with breast cancer. J. Nail Cancer Inst. (1975) 55:791–795.
   PubMed Web of Science ®Google Scholar
• KEW MC, TORRANCE JD, DERMAN D et al: Serum andtumour ferritins in primary liver cancer. Gut (1978) 19:294–299.
   PubMed Web of Science ®Google Scholar
• HANN HW, LEVY HM, EVANS AE: Serum ferritin as aguide to therapy in neuroblastoma. Cancer Res. (1980) 40:1411–1413.
   PubMed Web of Science ®Google Scholar
• ZHOU XD, STAHLHUT MW, HANN HL, LONDON WT: Serum ferritin in hepatocellular carcinoma. Hepatogas-troenterol. (1988) 35:1–4.
   PubMed Web of Science ®Google Scholar
• MUNRO HN, UNDER MC: Ferritin: structure, biosyn-thesis and role in iron metabolism. Physiol Rev. (1978) 58:317-396. IANCU TC, SHILOH H, KEDAR A: Neuroblastomas contain iron-rich ferritin. Cancer (1988) 61:2497-2502. IANCU TC: Iron and neoplasia: ferritin and hemosid-erin in tumor cells. Ultrastruct. Pathol. (1989) 13:573-584. Development of Iron Chelators for Clinical Use. Martell AE, Anderson WF, Badman DG (Eds.), Elsevier, North-Holland (1981).
   Google Scholar
• OLIVIERI NF, BRITTENHAM GM, MCLAREN CE et al.: Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl. J. Med. (1998) 339:417–423.
   PubMed Web of Science ®Google Scholar
• HOFFBRAND AV, AL-REFAIE F, DAVIS B et al.: Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood (1998) 91:295–300.
   PubMed Web of Science ®Google Scholar
• AL REFAIE FN, WONKE B, HOFFBRAND AV: Deferiprone-associated myelotoxicity. Eur. J. Hematol. (1994) 53:298–301.
   PubMed Web of Science ®Google Scholar
• AL REFAIE FN, HERSHKO C, HOFFBRAND AV et al.: Results of long-term deferiprone therapy (Li) therapy: A report by the international study group on oral iron chelators. Br. J. Haematol (1995) 91:224–229.
   PubMed Web of Science ®Google Scholar
• PORTER JB: A risk-benefit assessment of iron-chelation therapy. Drug Saf (1997) 17:407–421.
   PubMed Web of Science ®Google Scholar
• BALFOUR JAB, FOSTER RH: Deferiprone: a review of its clinical potential in iron overload in f3-thalassemia major and other transfusion-dependent diseases. Drugs (1999) 58:553–578.
   PubMed Web of Science ®Google Scholar
• FLORENCE A, LONGUEVILLE A, CRICHTON RR: Oral ironchelators may do more harm than good. Proceedings of the Ninth International Conference on Proteins of Iron Transport and Storage. July 9–13, Brisbane, Australia (1989):118.
   Google Scholar
• HIDER RC, LIU ZD, LIU DY, LU SL, KHODR H,PIYAMONGKOL S: The design of non-toxic orally active iron chelators. Proceedings of the World Congress on IronMetabolism BIOIRON'99.' Sorrento, Naples, Italy (1999):22.
   Google Scholar
• PONKA P, BOROVA J, NEUWIRT J, FUCHS 0: Mobiliza-tion of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett. (1979) 97:317–321.
   Google Scholar
• PONKA P, BOROVA J, NEUWIRT J, FUCHS 0, NECAS E: A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents. Biochim. Biophys. Acta (1979) 586:278–297.
   PubMed Web of Science ®Google Scholar
• HOY T, HUMPHREYS J, JACOBS A, WILLIAMS A, PONKA P: Effective iron chelation following oral adminstration of an isoniazid pyridoxal hydrazone. Br. J. Haematol (1979) 43:443–449.
   PubMed Web of Science ®Google Scholar
• CIKRT M, PONKA P, NECAS E, NEUWIRT J: Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone. Br. J. Haematol (1980) 45:275–283.
   PubMed Web of Science ®Google Scholar
• HERSHKO C, LINK G, TZAHOR M et al.: Anthracycline toxicity is potentiated by iron and inhibited by deferoxamine. Studies in rat heart cells in culture. J. Lab. Clin. Med. (1993) 122:245–251.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, HEFTER GT, MAY PM et al.: Ironchelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(ID, magnesium (ID, and zinc (ID . Biol. Metals (1989) 2:161–167.
   Google Scholar
• RICHARDSON DR, WIS VITOLO ML, HEFTER GT, MAY PM,CLARE BW, WEBB J, WILIARAT P: Iron chelators of the pyridoxal isonicotinoyl hydrazone class part 1. Ionisa-tion characteristics of the ligands and their relevance to biological properties. Inorg. Chim. Acta (1990) 170:165–170.
   Google Scholar
• VITOLO LMW, HEFTER GT, CLARE BW, WEBB J: Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(ID. Inorg. Chim. Acta (1990) 170:171–176.
   Web of Science ®Google Scholar
• BRITTENHAM GM: Pyridoxal isonicotinoyl hydrazone:an effective chelator after oral administration. Semin. Hematol (1990) 27:112–116.
   PubMed Web of Science ®Google Scholar
• EDWARD JT, GAUTHIER M, CHUBB FL, PONKA P: Synthesis of new acylhydrazones as iron-chelating compounds. J. Chem. Eng. Data (1988) 33:538–540.
   Web of Science ®Google Scholar
• BLAHA K, CIKRT M, NERUDOVA J, FORNUSKOVA H, PONKA P: Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone. Blood (1998) 91:4368–4372.
   PubMed Web of Science ®Google Scholar
• RICHARDSON D, BAKER E, PONKA P, WILAIRAT P, VITOLO ML, WEBB J: Effects of pyridoxal isonicotinoyl hydrazone and analogs on iron metabolism in hepato-cytes and macrophages in culture. Birth Defects (1988) 23 (5B):81–88.
   Google Scholar
• PONKA P, RICHARDSON D, BAKER E, SCHULMAN HM,EDWARD JT: Effect of pyridoxal isonicotinoyl hydrazone and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes. Biochim. Biophys. Acta (1988) 967:122–129.
   PubMed Web of Science ®Google Scholar
• BAKER E, RICHARDSON DR, GROSS S, PONKA P: Evalua- tion of the iron chelation potential of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology (1992) 15:492–501.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, BAKER E, VITOLO LW, WEBB J: Pyridoxal isonicotinoyl hydrazone and analogues. Study of their stability in acid, neutral and basic aqueous solutions by ultraviolet-visible spectropho-tometry. Biol. Metals (1989) 2:69–76.
   Google Scholar
• RICHARDSON DR, TRAN E, PONKA P: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood (1995) 86:4295–4306.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, MILNES K: The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: The mechanism of action of ligands derived from salicylal-dehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood (1997) 89:3025–3038.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR: Analogues of pyridoxal isonicoti-noyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia. Leukemia and Lymphoma (1998) 31:47–60.
   PubMed Web of Science ®Google Scholar
• DARNELL G, RICHARDSON DR: The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: The effect of the ligands on molecular targets involved in prolif-eration. Blood (1999) 94:781–792.
   PubMed Web of Science ®Google Scholar
• SHERR CJ: G1 phase progression: Cycling on cue. Cell (1994) 79:551–555.
   PubMed Web of Science ®Google Scholar
• LEVINE AJ: p53, the cellular gatekeeper for growth and division. Cell (1997) 88:323–331.
   PubMed Web of Science ®Google Scholar
• AGARWAL ML, TAYLOR WR, CHERNOV MV, CHERNOVA OB, STARK GR: The p53 network. J. Biol. Chem. (1998) 273:1–4.
   PubMed Web of Science ®Google Scholar
• BECKER E, RICHARDSON DR: Development of novelaroylhydrazone ligands for iron chelation therapy: The 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCII-I) analogues. J. Lab. Clin. Med. (1999) 134:510–521.
   PubMed Web of Science ®Google Scholar
• NICK HP, ACKLAND P, FALLER B et al.: ICL670A: A new, potent, orally active iron chelator. Proceedings of the World Congress on Iron Metabolism BIOIRON'991 Sorrento, Naples, Italy (1999):23.
   Google Scholar
• PIGA A, LOEHRER F, ALBERTI D, GALANELLO R: A novel iron chelator (ICL670A): update on a Phase I single dose safety study. Proceedings of the World Congress on Iron Metabolism BIOIRON'99.' Sorrento, Naples, Italy (1999):23.
   Google Scholar
• BLATT J, STITELY S: Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res. (1987) 47:1749–1750.
   PubMed Web of Science ®Google Scholar
• BECTON DL, BRYLES P: Deferoxamine inhibition ofhuman neuroblastoma viability and proliferation. Cancer Res. (1988) 48:7189–7192.
   PubMed Web of Science ®Google Scholar
• BLATT J, TAYLOR SR, STITELY S: Mechanism of antineu-roblastoma activity of deferoxamine in vitro. J. Lab. Clin. Med. (1988) 112:433–436.
   PubMedGoogle Scholar
• BECTON DL, ROBERTS B: Antileukemic effects ofdesferrioxamine on human myeloid leukemia cell lines. Cancer Res. (1989) 49:4809–4812.
   PubMed Web of Science ®Google Scholar
• DONFRANCESCO A, DEB G, DOMINICI C, PILEGGI D, CASTELLO MA, HELSON L: Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res. (1990) 50:4929–4930.
   PubMed Web of Science ®Google Scholar
• DONFRANCESCO A, DEB G, DE SIO L, COZZA R, CASTEL-LANO A: Role of desferrioxamine in tumor therapy. Acta Haematol. (1996) 95:66–69.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR: Iron chelators as effectiveanti-proliferative agents. Can. J. Physiol. Pharmacol (1997) 75:1164–1180.
   PubMed Web of Science ®Google Scholar
• THELANDER L, REICHARD P: The reduction of ribonu-cleotides. Ann. Rev. Biochem. (1979) 48:133–158.
   PubMed Web of Science ®Google Scholar
• THELANDER L, GRASLUND A, THELANDER M: Continual presence of oxygen and iron is required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. (1983) 110:859–865.
   PubMed Web of Science ®Google Scholar
• SELIG RA, WHITE L, GRAMACHO C, STERLINGLEVIS K, FRASER IW, NAIDOO D: Failure of iron chelators to reduce tumor growth in human neuroblastoma xenografts. Cancer Res. (1998) 58:473–478.
   PubMed Web of Science ®Google Scholar
• JOHNSON DK, MURPHY TB, ROSE NJ, GOODWIN WH,PICKART L: Cytotoxic chelators and chelates. 1. Inhibi-tion of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone. Inorg. Chim. Acta (1982) 67:159–165.
   Google Scholar
• PICKART L, GOODWIN WH, BURGUA W, MURPHY TB, JOHNSON DK: Inhibition of the growth of cultured cells and an implanted fibrosarcoma by aroylhydra-zone analogs of the Gly-His-Lys-Cu(I0 complex. Biochem. Pharmacol. (1983) 32:3868–3871.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR: Mobilization of iron from neoplastic cells by some iron chelators is an energy-dependent process. Biochim. Biophys. Acta (1997) 1320:45–67.
   PubMed Web of Science ®Google Scholar
• LEDERMAN HM, COHEN A, LEE JWW, FREEDMAN MH, GELFAND EW: Deferoxamine: A reversible S phase inhibitor of human lymphocyte proliferation. Blood (1984) 64:748–753.
   PubMed Web of Science ®Google Scholar
• BRODIE C, SIRIWARDANA G, LUCAS J et al.: Neuroblas-toma sensitivity to growth inhibition by deferox-amine: Evidence for a block in the G1 phase of the cell cycle. Cancer Res. (1993) 53:3968–3975.
   PubMed Web of Science ®Google Scholar
• NYHOLM S, MANN GJ, JOHANSSON AG, BERGERON RJ, GRASLUND A, THELANDER L: Role of ribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. (1993) 268:26200–26205.
   PubMed Web of Science ®Google Scholar
• COOPER CE, LYNAGH GR, HOYES KP, HIDER RC, CAMMACK R, PORTER JB: The relationship ofribonucleotide reductase in inhibition of mammalian cell growth by potent iron chelators. J. Biol. Chem. (1993) 268:26200–26205.
   PubMed Web of Science ®Google Scholar
• DAVIDOFF AM, PENCE JC, SHORTER NA, INGELHART JD,MARKS JR: Expression of p53 in human neuroblas-toma- and neuroepithelioma-derived cell lines. Oncogene (1992) 7:127–133.
   PubMed Web of Science ®Google Scholar
• BI S, HUGHES T, BUNGEY J, CHASE A, DE FABRITIIS P,GOLDMAN JA: p53 in chronic myeloid leukemia cell lines. Leukemia (1992) 6:839–842.
   PubMed Web of Science ®Google Scholar
• EHINGER M, NILSSON E, PERSSON A-M, OLSSON I,GULLBER U: Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentia-tion of the leukemic cell line K562. Cell Growth and Differentiation (1995) 6:9–17.
   PubMedGoogle Scholar
• JOHNSON P, GRAY D, MOWAT M, BENCHIMOL S: Expres-sion of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol. Cell Biol. (1991) 11:1–11.
   PubMed Web of Science ®Google Scholar
• MOLL UM, OSTERMEYER AG, HALADAY R, WINKFIELD B,FRAZIER M, ZAMBETTI G: Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. (1996) 16:1126–1137.
   PubMed Web of Science ®Google Scholar
• FRENCH FA, BLANZ EJ JR, SCHADDIX SC, BROCKMAN RW: a-(N)-Formylheteroaromatic thiosemicarbazones. Inhibition of tumor derived ribonucleoside diphos-p hate reductase and correlation with in vivo anti-tumor activity. J. Med. Chem. (1974) 17:172–181.
   Google Scholar
• AGRAWAL KC, SARTORELLI AC: The chemistry and biological activity of a-(N)-heterocyclic carboxalde-hyde thiosemicarbazones. Prog. Med. Chem. (1978) 15:321–356.
   PubMedGoogle Scholar
• LIU M-C, UN T-S, SARTORELLI AC: Chemical and biological properties of cytotoxic a-(N)-heterocyclic carboxaldehyde thiosemicarbazones. In: Progress in Medicinal Chemistry, Volume 32, Ellis GP, Luscombe DK (Eds.), Elsevier Science B.V. (1995):1–35.
   Google Scholar
• DECONTI RC, TOFTNESS BR, AGRAWAL KC et al: Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res. (1972) 32:1455–1462.
   PubMed Web of Science ®Google Scholar
• KRAKOFF IH, ETCUBANAS E, TAN C, MAYER K, BETHUNE V, BURCHENAL JH: Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP; NSC 107392), with special reference to its iron chelating properties. Cancer Chemother. Rep. (1974) 58:207–212.
   PubMedGoogle Scholar
• THELANDER L, GRASLUND A: Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. J. Biol. Chem. (1983) 258:4063–4066.
   PubMed Web of Science ®Google Scholar
• MILLER MC III, STINEMAN CN, VANCE JR, WEST DX, HALL IH: Multiple mechanisms for cytotoxicity induced by copper(H) complexes of 2-acetylpyrazine-N-substituted thiosemicarbazones. Appl. Organometal. Chem. (1999) 13:9–19.
   Web of Science ®Google Scholar
• TORTI SV, TORTI FM, WHITMAN SP, BRECHBIEL MW, PARK G, PLANALP RP: Tumor cell cytotoxicity of a novel metal chelator. Blood (1998) 92:1384–1389.
   PubMed Web of Science ®Google Scholar
• TORTI SV, WILLINGHAM MC, JENNINGS-GEE J et al.: Iron chelation in cancer therapy. Proceedings of the World Congress on Iron Metabolism BIOIRON'99.' Sorrento, Naples, Italy (1999):20.
   Google Scholar
• MEYERS FH, JAWETZ E, GOLDFIEN A: Review of Medical Pharmacology. 7th Ed, Lange Medical Publications, Los Altos, California, USA (1980).
   Google Scholar
• DORR RT: Cytoprotective agents for anthracyclines. Semin. Oncol (1996) 23:23–34.
   PubMed Web of Science ®Google Scholar
• MAY PM, WILLIAMS GK, WILLIAMS DR: Speciation studies of adriamycin, quelamycin, and their metal complexes. Inorg. Chim. Acta (1980) 46:221–228.
   Web of Science ®Google Scholar
• HASINOFF BB, DAVEY JP: The iron(III)-adriamycin complex inhibits cytochrome c oxidase before its inactivation. Biochem. J. (1998) 250:827–834.
   Google Scholar
• GIANNI L, VIGAN L, NIGGELER M et al.: Human ferritin (HLF) as iron source for lipid peroxidation by adriamycin (adr). Proc. Am. Assoc. Cancer Res. (1988) 29:378. (Abstract).
   Google Scholar
• MINOTTI G: Adriamycin-dependent release of iron from microsomal membranes. Arch. Biochem. Biophys. (1989) 268:398–403.
   PubMed Web of Science ®Google Scholar
• HERMAN EH, WITIAK DT, HELLMAN K et al.: Biological properties of ICRF-159 and related bis(dioxopipera-zine) compounds. Adv. Pharmacol Chemother. (1982) 19:249–301.
   PubMedGoogle Scholar
• HERMAN EH, FERRANS VJ: Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits. Cancer Chemother. Pharmacol. (1986) 16:102–106
   PubMed Web of Science ®Google Scholar
• DARDIR M, HERMAN EH, FERRANS VJ: Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats. Cancer Chemother. Pharmacol. (1989) 23:267–275.
   Google Scholar
• YEUNG TK, JAENKE RS, WILDING D et al: The protective activity of ICRF-187 against doxorubicin-induced cardiotoxicity in the rat. Cancer Chemother. Pharmacol (1992) 30:58–64.
   PubMed Web of Science ®Google Scholar
• SEIFERT CF, NESSER ME, THOMPSON DF: Dexrazoxane in the prevention of doxorubicin-induced cardiotox-icity. Ann. Pharmacother. (1994) 28:1063–1072.
   PubMed Web of Science ®Google Scholar
• WOODMAN RJ, CYSYK RL, KLINE I et al: Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943). Cancer Chemother. Rep. (1975) 59:689–695.
   PubMedGoogle Scholar
• GIULIANI F, CASAZZA AM, DI MARCO A et al.: Studies in mice treated with ICRF-159 combined with daunoru-bicin or doxorubicin. Cancer Treat Rep. (1981) 65:267–276.
   Google Scholar
• CAFFREY EA, DAKER MG, HORTON JJ: Acute myeloid leukemia after treatment with razoxane. Br. J. Dermatol. (1985) 113:131–134.
   PubMed Web of Science ®Google Scholar
• ATHERTON DJ, WELLS RS, LAURENT MR et al.: Razoxane (ICRF-159) in the treatment of psoriasis. Br. J. Dermatol. (1980) 102:307–317.
   PubMed Web of Science ®Google Scholar
• SPEYER JL, GREEN MD, KRAMER E et al.: Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer. N. EngL J. Med. (1988) 319:745–752.
   PubMed Web of Science ®Google Scholar
• SPEYER JL, GREEN MD, ZELENIUCH-JACQUOTTE A et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J. Gin. Oncol. (1992) 10:117–127.
   Web of Science ®Google Scholar
• DOROSHOW JH: Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents. Biochem. Biophys. Res. Commun. (1986) 135:330–335.
   PubMed Web of Science ®Google Scholar
• HASINOFF BB, DAVEY JP: Adriamycin and its iron(Ill) and coppern complexes. Biochem. Pharmacol. (1988) 37:3663–3669.
   PubMed Web of Science ®Google Scholar
• MARSH K, SNOW RW: 30 years of science and technology: the example of malaria. Lancet (1997) 349 (Suppl. III):1–2.
   Google Scholar
• GORDEUK VR, THUMA PE, BRITTENHAM GM et al.: Iron chelation therapy with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood (1992) 79:308–312.
   PubMed Web of Science ®Google Scholar
• MABEZA GF, BIEMBA G, GORDEUK VR: Clinical studies of iron chelators in malaria. Acta Haematol. (1996) 95:78–86.
   PubMed Web of Science ®Google Scholar
• GORDEUK VR, THUMA P, BRITTENHAM G et al: Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl. J. Med. (1992) 327:1473–1477.
   PubMed Web of Science ®Google Scholar
• WEISS G, THUMA PE, MABEZA G, WERNER ER, HEROLD M, GORDEUK VR: Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. J. Infect. Dis. (1997) 175:226–230.
   PubMed Web of Science ®Google Scholar
• PATTANAPANYASAT K, THAITHONG S, KYLE DE et al: Flow cytometric assessment of hydroxypyridone iron chelators on in vitro growth of drug-resistant malaria. Cytometty (1997) 27:84–91.
   PubMedGoogle Scholar
• SCOTT MD, RANZ A, KUYPERS FA, LUBIN BH, MESHNICK SR: Parasite uptake of desferrioxamine: a prerequisite for antimalarial activity. Br. J. HaematoL (1990) 75:598–603.
   PubMed Web of Science ®Google Scholar
• TSAFACK A, GOLENSER J, LIBMAN J, SHANZER A, CABANTCHIK ZI: Mode of action of iron(Ill) chelators as antimalarials. 3. Overadditive effects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum. Mol. Pharmacol. (1995) 47:403–409.
   Google Scholar
• CHEVION M, CHUANG L, GOLENSER J: Effects of zinc-desferrioxamine on Plasmodium falciparum in culture. Antimicrob. Agents Chemother. (1995) 39:1902–1905.
   PubMed Web of Science ®Google Scholar
• GOLDBERG DE, SHARMA V, OKSMAN A, GLUZMAN IY, WELLEMS TE, PIWNICAWORMS D: Probing the chloroquine-resistant locus of Plasmodium falciparum with a novel class of multidentate metal(III) coordination complexes. J. Biol. Chem. (1997) 272:6567–6572.
   PubMed Web of Science ®Google Scholar
• SHARMA V, BEATTY A, GOLDBERG DE, PIWINCAWORMS D: Structure of a novel antimalarial gallium(III) complex with selective activity against chloroquine-resistant Plasmodium falciparum. Chem. Commun. (1997) 22:2223–2224.
   Web of Science ®Google Scholar
• DELANGHE JR, LANGLOIS MR, BOELAERT JR et al.: Haptoglobin polymorphism, iron metabolism and mortality in HIV infection. AIDS (1998) 12:1027–1032.
   PubMed Web of Science ®Google Scholar
• MATEOS F, GONZALEZ C, DOMINGUEZ C, LOSA JE, JIMENEZ A, PEREZ-ARELLANO JL: Elevated non-transferrin bound iron in the lungs of patients with Pneumocystis carinii pneumonia. J. Infect. (1999) 38:18–21.
   PubMed Web of Science ®Google Scholar
• SAPPEY C, BOELAERT JR, LEGRANDPOELS S, FORCEILLE C, FAVIER A, PIETTE J: Iron chelation decreases NF-kappa B and HIV Type 1 activation due to oxidative stress. AIDS Res. Hum. Retrovir. (1995) 11:1049–1061.
   PubMed Web of Science ®Google Scholar
• SHATROV VA, BOELAERT JR, CHOUAIB S, DROUGE W, LEHMANN V: Iron chelation decreases human immunodeficiency virus-1 Tat potentiated tumor necrosis factor-induced NF-kappa B activation in Jurkatt cells. Eur. Cytokine Netw. (1997) 8:37–43.
   PubMed Web of Science ®Google Scholar
• SIMONART T, NOEL JC, ANDREI G et al.: Iron as a potential co-factor in the pathogenesis of Kaposi's sarcoma. Int. J. Cancer (1998) 78:720–726.
   PubMed Web of Science ®Google Scholar
• MALLERY SR, CLARK YM, NESS GM, MINISHAWI OM, PEI P, HOHL CM: Thiol redox modulation of doxorubicin mediated cytotoxicity in cultured AIDS-related Kaposi's sarcoma cells. J. Cell. Biochem. (1999) 73:259–277.
   PubMed Web of Science ®Google Scholar
• WEINBERG GA: Iron chelators as therapeutic agents against Pneumocystis carinii. Antimicrob. Agents Chemother. (1994) 38:997–1003.
   PubMed Web of Science ®Google Scholar
• BABCOCK M, DE SILVA D, OAKS R et al.: Regulation of mitochondrial iron accumulation by Yfhlp, a putative homologue of frataxin. Science (1997) 276:1709–1712.
   PubMed Web of Science ®Google Scholar
• FOURY F, CAZZALINI 0: Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia elicits iron accumulation in mitochondria. FEBS Lett. (1997) 411:373–377.
   PubMed Web of Science ®Google Scholar
• ROTIG A, DE LONLAY P, CHRETIEN D et al.: Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nature Genet. (1997) 17:215–217.
   PubMed Web of Science ®Google Scholar
• RADISKY DC, BABCOCK MC, KAPLAN J: The yeast frataxin homologue mediates mitochondrial iron efflux: Evidence for a mitochondrial iron cycle. J. Biol. Chem. (1999) 274:4497–4499.
   PubMed Web of Science ®Google Scholar
• LAMARCHE JB et al.: In: Handbook of Cerebellar Diseases. R Lectenberg (Ed.) Dekker, New York (1993):453–457.
   Google Scholar
• MORGAN RO, NAGLI G, HORROBIN DF, BARBEAU A: Erythrocyte protoporphyrin levels in patients with Friedreich's and other ataxias. Can. J. Neurol. ScI (1979) 6:227–232.
   PubMed Web of Science ®Google Scholar
• SMITH JC, KUSHNER JP, BROMBERG M et al.: Evidence for mitochondrial iron overload in patients with Friedrei-ch's ataxia. Proceedings of the International Friedreich's Ataxia Conference. The National Institutes of Health, Bethesda, Maryland, USA, 1999.
   Google Scholar
• RICHARDSON D, PONKA P, BAKER E: The effect of the iron(II) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell. Cancer Res. (1994) 54:685–689.
   PubMed Web of Science ®Google Scholar
• BOROVA J, PONKA P, NEUWIRT J: Study of intracellular iron distribution in rabbit reticulocytes with normal and inhibited heme synthesis. Biochim. Biophys. Acta (1973) 320:143–156.
   PubMed Web of Science ®Google Scholar
• PONKA P, WILCZYNSKA A, SCHULMAN HM: Iron utiliza-tion in rabbit reticulocytes. A study using succinylace-tone as an inhibitor of heme synthesis. Biochim. Biophys. Acta (1982) 720:96–105.
   PubMed Web of Science ®Google Scholar
• ADAMS ML, OSTAPIUK I, GRASSO JA: The effects of inhibition of heme synthesis on the intracellular localisation of iron in rat reticulocytes. Biochim. Biophys. Acta (1989) 1012:243–253.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, PONKA P, VYORAL D: Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates of iron metabolism. Blood (1996) 87:3477–3488.
   PubMed Web of Science ®Google Scholar
• RICHARDSON DR, BECKER E, BERNHARDT PV: The biologically active iron chelators 2-pyridyl-carboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone. Acta Crystallo-graphica Section C (1999). (In Press).
   Google Scholar
• RICHARDSON DR, BERNHARDT PV, BECKER E: Novel iron chelators (Provisional Patent Submission).
   Google Scholar